Why Is Integra LifeSciences Stock Tumbling Today? IART Falls After Guidance Cut
Integra LifeSciences (NASDAQ: IART) stock is tumbling today after the medical-device company lowered its full-year 2026 revenue and adjusted earnings guidance, citing continued disruption from flooding at its Cincinnati manufacturing facility. The company also released preliminary third-quarter results that point to weaker revenue and earnings than previously expected.
Shares were down roughly 14% in morning trading on October 2, according to market data, after falling as much as 11% in premarket trading. The sell-off followed Integra's announcement before the market opened.
The central issue for investors is not simply one weak quarter. Integra now expects the Cincinnati disruption to affect fourth-quarter revenue as well, with the facility not expected to return to full manufacturing operations until the second quarter of 2027.
The main reason IART stock is falling today
Integra said its preliminary third-quarter 2026 revenue is expected to be approximately $410 million to $412 million, while adjusted earnings per diluted share are expected at $0.55 to $0.59.
More importantly, the company cut its full-year outlook.
Its previous 2026 reported revenue guidance was $1.654 billion to $1.695 billion. That range has now been reduced to $1.634 billion to $1.654 billion.
Adjusted EPS guidance has also been lowered from $2.40-$2.50 to $2.30-$2.40.
For investors, a guidance cut is often more significant than a single quarterly miss because it changes management's expectations for the business over the remainder of the year.
Cincinnati flooding continues to hurt production
The immediate operational problem dates back to a July 2026 flooding event at Integra's Cincinnati facility.
The flooding damaged portions of the facility, equipment, inventory and other assets. The site manufactures and supports products within Integra's Specialty Surgical Technologies portfolio.
Integra has been using existing inventory, alternate suppliers and recovery measures to limit the disruption. However, the company now estimates that the flooding reduced third-quarter revenue by approximately $7 million.
The impact is expected to continue into the fourth quarter, with Integra estimating another $15 million to $20 million hit to revenue. Full manufacturing operations at the facility are currently expected to return during the second quarter of 2027.
That extended recovery timeline appears to be a major reason investors are selling the stock today.
The impact is larger than the third-quarter numbers
The preliminary third-quarter figures themselves are not the only concern.
Integra said the flooding-related disruption, together with updated assumptions for the broader business, has led it to reduce its full-year expectations. That means investors are now recalibrating their estimates for revenue and earnings for the remainder of 2026.
The company still expects $190 million to $200 million of operating cash flow for 2026, suggesting that the business continues to generate substantial cash despite the manufacturing disruption. Management also expects more than $85 million of operating cash flow in the third quarter.
So the current sell-off is not necessarily a signal that Integra's entire business model has deteriorated. Rather, the market is responding to a combination of operational disruption, lower guidance and uncertainty around the pace of recovery.
Integra is also refinancing $600 million of debt
Another important development announced on October 2 is Integra's proposed $600 million seven-year Senior Secured Term Loan B.
The company plans to use the proceeds, along with other financing sources, to refinance certain existing debt and pay associated fees and expenses. Integra said the refinancing is intended to extend maturities and maintain financial flexibility.
Debt refinancing can be positive from a liquidity-management perspective because extending maturities can reduce near-term repayment pressure.
However, the proposed financing also matters because investors are evaluating the company at a time when operations are under pressure. The final size, pricing and terms of the transaction remain subject to market conditions and customary closing requirements, and Integra said there is no assurance about when or whether the financing will be completed.
That makes the debt market an additional factor to watch alongside the manufacturing recovery.
How Integra was performing before the latest update
The latest weakness comes after a mixed first half of 2026.
In the second quarter, Integra reported $418.8 million in revenue, up 0.8% on a reported basis and 0.7% organically from the previous year. Adjusted EPS was $0.56, compared with $0.45 a year earlier.
At that time, the company reaffirmed its 2026 organic revenue growth guidance of 0.8% to 3.3% and adjusted EPS guidance of $2.40 to $2.50, while noting the potential impact of tariffs, interest rates and debt refinancing.
The October update therefore represents a meaningful change from the outlook investors received only a few months ago.
Insurance could offset part of the damage
One factor that could help limit the financial impact is insurance coverage.
Integra said it maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the company expects insurance recoveries to mitigate a substantial portion of the earnings impact associated with the disruption during the recovery period.
However, the company is still working with its insurance carrier to assess and document recoverable losses. Therefore, the amount and timing of any eventual recovery remain uncertain.
This distinction is important: insurance may reduce the ultimate economic cost, but it does not eliminate the immediate manufacturing and revenue disruption.
What the sell-off means for investors
The market reaction reflects three issues that are now closely connected.
First, revenue expectations have fallen. Integra expects the Cincinnati disruption to reduce revenue in both the third and fourth quarters.
Second, earnings guidance has been reduced. Adjusted EPS is now expected to be $2.30-$2.40 for 2026, below the previous $2.40-$2.50 range.
Third, the recovery timeline remains long. Full manufacturing operations at Cincinnati are not expected until the second quarter of 2027.
At the same time, Integra continues to expect significant operating cash flow and says product availability and commercial execution are improving.
That creates a more nuanced picture than simply "bad earnings." The company is dealing with a specific manufacturing disruption, while management says the broader business is making progress.
What investors should watch next
The next major catalyst will be Integra's official third-quarter earnings release and conference call, when management is expected to provide more detail on revenue, margins, product availability, recovery costs and the updated outlook.
Investors should particularly monitor:
- Progress at the Cincinnati facility and the timeline toward full production.
- Actual third-quarter revenue and adjusted EPS versus the preliminary figures.
- Fourth-quarter revenue impact from the disruption.
- Insurance recovery estimates and timing.
- Completion and pricing of the proposed $600 million refinancing.
- Cash flow and debt levels.
- Product availability across the Specialty Surgical Technologies portfolio.
The recovery schedule will be particularly important because the current expectation extends well into 2027.
Conclusion
Integra LifeSciences stock is tumbling today because the company lowered its 2026 financial guidance after determining that flooding at its Cincinnati facility will have a larger and longer-lasting impact on operations than previously expected. The company now expects full-year revenue of $1.634 billion to $1.654 billion and adjusted EPS of $2.30 to $2.40.
The proposed $600 million debt refinancing adds another important element to the story, although Integra continues to forecast substantial operating cash flow and expects insurance recoveries to offset a significant portion of the flood-related earnings impact.
For investors, the key question now is how quickly production can normalize and whether Integra can protect cash flow and margins while the Cincinnati facility works toward a full recovery in 2027.
Follow the blog for more updates on U.S. stocks, healthcare companies, earnings, corporate developments and global markets.
This article is for informational and educational purposes only and should not be considered investment advice.